Twelves, Chris - University of Bradford - School of Medical Sciences

研究领域

Early drug development and the pharmacology of anticancer drugs. Clinical practice in breast and colorectal cancer

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Twelves C. Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Expert Rev Anticancer Ther. 2013 Mar;13(3):251-5. doi: 10.1586/era.13.3. PubMed PMID: 23477510 Seligmann J, Twelves C. Tubulin: an example of targeted chemotherapy. Future Med Chem. 2013 Mar;5(3):339-52. doi: 10.4155/fmc.12.217. PubMed PMID: 23464522 Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536. PubMed PMID: 23170896; PubMed Central PMCID: PMC3517777 Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012 May;23(5):1190-7. doi: 10.1093/annonc/mdr366. Epub 2011 Sep 6. PubMed PMID: 21896539 Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16. PubMed PMID: 21576084; PubMed Central PMCID: PMC3131422 Twelves C, Vahdat LT, Cortés J. Novel treatment options in the management of metastatic breast cancer. Clin Adv Hematol Oncol. 2011 May;9(5 Suppl 10):1-16. PubMed PMID: 21738118 Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. PubMed PMID: 21376385 Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010 Apr;10(2):160-3. doi: 10.3816/CBC.2010.n.023. PubMed PMID: 20299316